Here are some tips on how to get the MOAB. Hope you guys enjoy the video! Please leave a like it helps a lot!!! Twitter: https://twitter.com/#!/xFLiGHT23 BOPS 2 perks video: http://youtu.be/fpWRRgzEFoY
50 percent of all dead people come back as zombies. They come back confused, hungry and in need of entertainment. The Zombie Today Show is for the modern zombie. Watch celebrity guests such as Elvis and Michael Jackson. Find out about zombie skin care and the Flesh Patch.
The Zombie Today Show is a soap opera comedy of zombies and Hollywood. In the spirit of Zombieland, Fido and Shaun of the Dead.
New episodes play each Friday at http://www.readersentertainment.tv
Blogs, photos, videos and polls await. Be one of those fast zombies. Get there quick and have some fun. Trip a friend. Feed them to Roger.
Missy is a 1 year old American Pit Bull Terrier / Boxer mix who is in foster care with EnchantMutts. For more information about Missy, check out her bio at: www.enchantmutts.org.
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Fuse needs a video reporter to help cover the John Mayer concert at NYC's Beacon Theatre on November 17th! You can win a trip for you and a friend to NYC including a 2 night stay at the Beacon Hotel, tickets to the sold out Beacon Theatre show, round trip airfare provided by Delta, and the chance to be on Fuse as you co-anchor a special segment of The Daily Noise with Billboard Editorial Director, Bill Werde. To enter, head to http://fuse.tv/johnmayer
http://www.colocationamerica.com/dedicated_servers/dedicated_specials.htm
Colocation America’s New Jersey location is a premier facility which offers technologically advanced dedicated servers, internet bandwidth, dynamic IPs and data storage options. Our SEO hosting plans can be customized to help you reach your marketing goals. Keeping our promise of 100% uptime year in and year out, your business is sure to thrive! Whether you prefer a Windows or Linux operating system, we’ve got you covered and supported by a team of professionals.
Writer/Director/Raconteur/Podcaster/Sinner (to some) and proud Jersey boy Kevin Smith returns to EPIX, bringing his unusual multi-talents in a one-man show, Kevin Smith Burn in Hell. The original comedy event premieres February 11 on the EPIX premium network. Additionally, EPIX is reaching out to Kevin Smith fans everywhere with an on demand preview beginning February 3, offering subscribers and non-subscribers an early screening of the entire special. The preview can be viewed via participating affiliated television providers’ EPIX On Demand service and EPIX apps on Xbox 360 and Roku. It will also be available for streaming at EpixHD.com and the “TV Everywhere” portals of affiliated providers.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52239-epix-hd-kevin-smith-burn-in-hell
Greetings from Johannesburg, South Africa. Join us as we catch up with two of the city’s rising young soccer stars, Nodia Mukari and Dylan Bufton. Both boys play for McDuling Motors, a Johannesburg based under thirteen side that is more commonly known as Robertsham Football Club. The team recently won the South African leg of the Volkswagen Junior Masters and as a result they will now be representing South Africa in the world finals, to be held in Madrid in May.
Description: Elvira Witsil’s difficult life in rural Wisconsin is made yet harder when her peculiar sister, Jessie, is discovered to be a seer. This powerful YA novel from Diana Greenwood leads a family on a journey far away from home, on a journey toward redemption and healing, if Elvira can just bring herself to believe. Learn more about this book here, http://bit.ly/fxf1EZ and its author here, http://bit.ly/hUHURI YA, Christian
Two Merck research scientists, Nancy A. Thornberry and Ann E. Weber, Ph.D., will receive the Discoverers Award, the highest honor from the Pharmaceutical Research and Manufacturers of America (PhRMA), during a ceremony tonight at the Liberty Science Center in Jersey City, N.J.
They will be recognized for their leadership in the discovery of JANUVIA®, a once-daily pill that helps patients with type 2 diabetes control glucose in conjunction with diet and exercise. Though women have been part of teams honored with the Discoverers Award in the past, this is the first time in the award’s 24-year history that women alone have won.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phrma/49723/
Even as women and men around the world celebrate the 100th anniversary of International Women’s Day on March 8th, violence against women remains a global epidemic. The domestic violence statistics for just one ordinary day in the United States are staggering: on average, three women will be murdered by an intimate partner i, more than 70,000 domestic violence victims will receive services from domestic violence programs and another 10,000 will be turned away for lack of resources, and domestic violence hotlines will receive more than 22,000 calls. Around the world, the statistics are equally horrific: one in three women will be raped, beaten, coerced into sex or otherwise abused in her lifetime.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/avonfoundation/48999/
